Can the Pharmaceutical Industry Restore its Broken Image?
E-Book, Englisch, 136 Seiten, E-Book
ISBN: 978-1-118-51125-1
Verlag: John Wiley & Sons
Format: EPUB
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Author John LaMattina, a thirty-year veteran of thepharmaceutical industry and former president of Pfizer's GlobalR&D Division, is internationally recognized as an expert on thepharmaceutical industry. His first book, Drug Truths: Dispellingthe Myths About Pharma R&D, was critically acclaimed forclearing up misconceptions about the pharmaceutical industry andproviding an honest account of the contributions of pharmaceuticalresearch and development to human health and well-being.
As he toured the country discussing Drug Truths, Dr.LaMattina regularly came across people who were filled with anger,accusing the pharmaceutical industry of making up diseases, hidingdangerous side effects, and more. This book was written in responseto that experience, critically examining public perceptions andindustry realities.
Starting with "4 Secrets that Drug Companies Don't Want You toKnow," Devalued and Distrusted provides a fact-based accountof how the pharmaceutical industry works and the challenges itfaces. It addresses such critical issues as:
* Why pharmaceutical R&D productivity has declined
* Where pharmaceutical companies need to invest theirresources
* What can be done to solve core health challenges, includingcancer, diabetes, and neurodegenerative diseases
* How the pharmaceutical industry can regain public trust andresuscitate its image
Our understanding of human health and disease grows daily;however, converting science into medicine is increasinglychallenging. Reading Devalued and Distrusted, you'll notonly gain a greater appreciation of those challenges, but also therole that the pharmaceutical industry currently plays and can playin solving those challenges.
Get to know the author: Read an interview with JohnLaMattina or watch a video on ChemistryViews!
Interview: JohnLaMattina: 30 Years in Pharma
Video: Canthe Pharmaceutical Industry Restory its Broken Image?
Autoren/Hrsg.
Weitere Infos & Material
ACKNOWLEDGMENTS ix
INTRODUCTION 1
CHAPTER 1 THE FOUR SECRETS THE DRUG COMPANIES DON'T WANTYOU TO KNOW 4
Drug Companies Underestimate Dangerous Side Effects 5
Drug Companies Control Much of the Information Your Doctor Gets10
You're Often Prescribed Drugs That You Don't Need14
Drugs Target the Symptoms, Not the Cause 19
Conclusion 22
References 23
CHAPTER 2 WHAT HAS HAPPENED TO R&D PRODUCTIVITY? 25
Impact of Mergers on R&D Productivity 26
Heightened FDA Requirements for NDAs 34
Higher Hurdles Set by Payers 41
Conclusion 46
References 48
CHAPTER 3 KEY THERAPEUTIC AREAS FOR IMPROVING HEALTH 49
Cancer 51
Diseases of the Brain 54
Cardiovascular Disease (CVD) 60
Diabetes 63
Bacterial Infections 65
Conclusion 68
References 69
CHAPTER 4 IMPROVING R&D OUTPUT 71
The Views of Others 72
Pharma's Blockbuster Mentality Needs to Change 72
Can "Predictive Innovation" Lead to Greater SuccessRates? 76
Would Royalties Make Scientists More Productive? 78
Will Drug Repositioning Help Fill the R&D Pipeline? 80
Consultants Don't Always Have the Facts 82
Personal Views 84
Discovery Must Focus on Productivity 85
Does Size Help or Hinder R&D Productivity? 87
To Outsource or Not to Outsource? That's the PharmaR&D Question 89
Big Pharma Early Research Collaborations 92
Conclusion 93
References 95
CHAPTER 5 RESTORING PHARMA'S IMAGE 96
Illegal Detailing of Drugs 97
Pharmaceutical Companies Should Drop TV Ads 98
The Need for Greater Transparency 100
How Committed Is Big Pharma to Rare Diseases? 102
Pharmaceutical Companies and Philanthropy 104
Pharma Needs to Have Its Scientists Tell Their Stories 105
Conclusion 106
References 107
CHAPTER 6 FINAL THOUGHTS 109
References 114
INDEX 115
